One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2020-137603
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2020 |
Affiliation: University of Lübeck, Rambam Health Care Campus, Tris Pharma (United States), University Hospital Carl Gustav Carus, Ospedale Niguarda Ca' Granda, Novartis (India), Leitat Technological Center, University of Brescia, Novartis (Switzerland), Seoul National University Hospital, Hôpital Cardiologique du Haut-Lévêque, Universität Hamburg, University Medical Center Hamburg-Eppendorf, Centre Hospitalier Universitaire de Nancy, Ankara University, Royal Brisbane and Women's Hospital, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Centre Hospitalier Universitaire de Grenoble, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Inserm, Université Paris Cité
Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
